Open AccessEffect of Metformin on Development of Tendinopathy Due to Mechanical Overloading in an Animal Model
Author(s) -
Jianying Zhang,
Feng Li,
Daibang Nie,
Kentaro Onishi,
MaCalus V. Hogan,
James H-C. Wang
Publication year - 2020
Publication title -
foot and ankle international
Language(s) - English
Resource type - Journals
eISSN - 1944-7876
pISSN - 1071-1007
DOI - 10.1177/1071100720966318
Subject(s) - tendinopathy , medicine , hmgb1 , proinflammatory cytokine , cd68 , tendon , tendinitis , immunohistochemistry , endocrinology , inflammation , pathology
Tendinopathy is a debilitating tendon disorder that affects millions of Americans and costs billions of health care dollars every year. High mobility group box 1 (HMGB1), a known tissue damage signaling molecule, has been identified as a mediator in the development of tendinopathy due to mechanical overloading of tendons in mice. Metformin (Met), a drug approved by the Food and Drug Administration used for the treatment of type 2 diabetes, specifically inhibits HMGB1. This study tested the hypothesis that Met would prevent mechanical overloading-induced tendinopathy in a mouse model of tendinopathy created by intensive treadmill running (ITR).